# Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

> **NCT03226574** · PHASE1 · COMPLETED · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Intractable Cancer Pain

## Interventions

- **DRUG:** Resiniferatoxin

## Key facts

- **NCT ID:** NCT03226574
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2020-03-18
- **Final completion:** 2020-06-18
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226574, "Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03226574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*